ENDRA Life Sciences Inc
-1.47 %
1113.86 %
Yet to be announced
Company Overview
ENDRA Life Sciences Inc. is a medical technology company focused on developing innovative medical imaging solutions. Their primary product under development is the Thermo Acoustic Enhanced UltraSound (TAEUS) system, which aims to enable clinicians to visualize human tissue composition, function, and temperature in ways previously possible only with CT and MRI - at a fraction of the cost.
The company is still in the development and clinical trial phase, with no commercial revenue generation yet. They are primarily focused on addressing the global Non-Alcoholic Fatty Liver Disease (NAFLD) epidemic.
Revenue Sources
PassAs ENDRA Life Sciences is still pre-revenue and in the development phase of their medical imaging technology, this criterion is not applicable at this time. The company's planned revenue model is based on selling medical imaging equipment and related services, which are halal activities.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Since the company is pre-revenue and still in R&D mode, we skip the usual interest ratio calculations. However, it's worth noting that the company has recorded significant interest expenses in recent quarters, particularly in Q3 2024. While this is concerning, it's typical for pre-revenue medical technology companies to utilize debt financing during their development phase.
Operational Ethics
PassBased on available information from SEC filings and company materials, ENDRA Life Sciences does not appear to have any significant ongoing associations with entities involved in human rights violations. The company's operations are primarily based in the United States, and there is no evidence of current material relationships with Israel or the Chinese Communist Party.
Comments